Silence Therapeutics PLC (LON:SLN) “Buy” Rating Maintained by Analysts at Peel Hunt; With GBX 275.00 Target; Fitbit, Inc. (FIT) Covered By 4 Bullish Analysts Last Week

Among 27 analysts covering Fitbit (NYSE:FIT), 4 have Buy rating, 4 Sell and 19 Hold. Therefore 15% are positive. Fitbit has $79 highest and $500 lowest target. $17.15’s average target is 191.17% above currents $5.89 stock price. Fitbit had 83 analyst reports since August 6, 2015 according to SRatingsIntel. The firm has “Hold” rating given on Thursday, November 2 by Stifel Nicolaus. Stifel Nicolaus maintained Fitbit, Inc. (NYSE:FIT) rating on Thursday, August 6. Stifel Nicolaus has “Buy” rating and $60 target. The rating was initiated by Cowen & Co on Thursday, September 10 with “Market Perform”. The firm earned “Neutral” rating on Thursday, August 6 by Dougherty & Company. The firm has “Buy” rating by Oppenheimer given on Monday, August 28. The stock of Fitbit, Inc. (NYSE:FIT) has “Equal-Weight” rating given on Thursday, November 3 by Morgan Stanley. The firm has “Outperform” rating by Oppenheimer given on Friday, May 5. The stock has “Overweight” rating by Piper Jaffray on Monday, August 24. Wedbush downgraded Fitbit, Inc. (NYSE:FIT) rating on Thursday, November 3. Wedbush has “Neutral” rating and $10 target. The stock of Fitbit, Inc. (NYSE:FIT) has “Neutral” rating given on Tuesday, February 23 by Barid. See Fitbit, Inc. (NYSE:FIT) latest ratings:

21/12/2017 Broker: Cleveland Rating: Hold
15/12/2017 Broker: Stifel Nicolaus Old Rating: Hold New Rating: Sell Downgrade
02/11/2017 Broker: Stifel Nicolaus Rating: Hold New Target: $6.0 Maintain
23/10/2017 Broker: Cowen & Co Rating: Hold New Target: $6.0 Maintain
20/10/2017 Broker: Morgan Stanley Rating: Equal-Weight Old Target: $6.5 New Target: $7 Maintain
07/09/2017 Broker: Stifel Nicolaus Rating: Hold New Target: $6.0 Maintain
01/09/2017 Broker: Robert W. Baird Rating: Hold New Target: $6.0
29/08/2017 Broker: Deutsche Bank Rating: Hold Maintain
29/08/2017 Broker: Raymond James Rating: Buy Maintain
28/08/2017 Broker: Oppenheimer Rating: Buy New Target: $8.0 Maintain

In a research report released on today, Peel Hunt reiterated their “Buy” rating on Silence Therapeutics PLC (LON:SLN)‘s stock. The target gives a potential upside of 39.24% from company’s current stock price.

Fitbit, Inc. designs and sells connected health and fitness tracking devices. The company has market cap of $1.40 billion. The firm offers Fitbit Zip, an entry-level wireless activity tracker that allows users to track daily activity statistics, such as steps, distance, calories burned, and active minutes; Fitbit One, a clippable wireless tracker, which tracks floors climbed and sleep, as well as daily steps, distance, calories burned, and active minutes; and Fitbit Flex 2, a water-resistant fitness wristband that tracks pool swims comprising laps, duration, and calories burned in the Fitbit App. It currently has negative earnings. It also provides Fitbit Alta, a customizable wristband that offers call, text, and calendar notifications when paired with the userÂ’s phone and SmartTrack automatic exercise recognition; Fitbit Charge 2, a wireless heart rate and activity wristband; Fitbit Blaze, a smart fitness watch that provides multi-sport functionality, tracks outdoor cycling activity, and run cues; and Fitbit Surge, a fitness watch that features a GPS watch, heart rate tracker, activity tracker, and smartwatch.

The stock decreased 1.34% or $0.08 during the last trading session, reaching $5.89. About 4.98 million shares traded. Fitbit, Inc. (NYSE:FIT) has declined 60.69% since December 28, 2016 and is downtrending. It has underperformed by 77.39% the S&P500.

The stock decreased 1.05% or GBX 2.11 during the last trading session, reaching GBX 198.39. About 370 shares traded. Silence Therapeutics plc (LON:SLN) has 0.00% since December 28, 2016 and is . It has underperformed by 16.70% the S&P500.

Silence Therapeutics plc focuses on the discovery, development, and delivery of RNA therapeutics. The company has market cap of 138.86 million GBP. The firm creates short interfering RNA molecules that trigger the RNAi pathway and mediate the degradation of specific target messenger RNAs. It currently has negative earnings. It is developing Atu027, a drug candidate that is in Phase IIa study for use in the treatment of pancreatic cancer, as well as various GalNAc-siRNA candidates for use in the treatment of iron overload disorders, acromegaly, cardiovascular disease, alcohol use disorder, and other metabolic diseases.

Among 2 analysts covering Silence Therapeutics PLC (LON:SLN), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Silence Therapeutics PLC has GBX 279 highest and GBX 233 lowest target. GBX 262’s average target is 32.06% above currents GBX 198.39 stock price. Silence Therapeutics PLC had 7 analyst reports since September 29, 2015 according to SRatingsIntel. The rating was maintained by Canaccord Genuity on Monday, January 9 with “Buy”. Canaccord Genuity maintained the shares of SLN in report on Thursday, August 11 with “Buy” rating. The stock of Silence Therapeutics plc (LON:SLN) has “Buy” rating given on Tuesday, December 20 by Canaccord Genuity. The stock of Silence Therapeutics plc (LON:SLN) earned “Buy” rating by Canaccord Genuity on Tuesday, September 29. The firm earned “Buy” rating on Tuesday, September 27 by Canaccord Genuity. The rating was maintained by Peel Hunt on Thursday, December 28 with “Buy”.